IRON
Disc Medicine, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.-38.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IRON vs RYTM
Revenue, margins, valuation, and 5-year total return — side by side.
RYTM
Rhythm Pharmaceuticals, Inc.
Biotechnology
Market Cap$6.59B
5Y Perf.+226.1%
IRON vs RYTM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IRON | RYTM |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2.58B | $6.59B |
| Revenue (TTM) | $0.00 | $217M |
| Net Income (TTM) | $-212M | $-204M |
| Gross Margin | — | 89.4% |
| Operating Margin | — | -90.9% |
| Total Debt | $2M | $246M |
| Cash & Equiv. | $91M | $54M |
IRON vs RYTM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IRON
RYTM
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | 100 | 61.4 | -38.6% |
| Rhythm Pharmaceutic… (RYTM) | 100 | 326.1 | +226.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IRON vs RYTM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IRON leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Rhythm Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
IRON
Disc Medicine, Inc.
The Income Pick
IRON carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.01
- Lower volatility, beta 1.01, Low D/E 0.3%, current ratio 21.94x
- Beta 1.01, current ratio 21.94x
Best for: income & stability and sleep-well-at-night
RYTM
Rhythm Pharmaceuticals, Inc.
The Growth Play
RYTM is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 45.8%, EPS growth 28.3%, 3Y rev CAGR 100.2%
- 220.8% 10Y total return vs IRON's -34.4%
- 45.8% revenue growth vs IRON's -94.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RYTM | 45.8% revenue growth vs IRON's -94.1% |
| Quality / Margins | IRON | 3.0% margin vs RYTM's -93.8% |
| Stability / Safety | IRON | Beta 1.01 vs RYTM's 1.04, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IRON | +55.1% vs RYTM's +48.9% |
| Efficiency (ROA) | IRON | -30.2% ROA vs RYTM's -45.2%, ROIC -38.0% vs -70.1% |
IRON vs RYTM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
IRON vs RYTM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRYTMLAGGINGIRON
IRONDisc Medicine, Inc.
1leads
RYTMRhythm Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs IRONMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RYTM1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IRON7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
RYTM5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RYTM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RYTM and IRON operate at a comparable scale, with $217M and $0 in trailing revenue.
| Metric | IRONDisc Medicine, In… | RYTMRhythm Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $217M |
| EBITDAEarnings before interest/tax | -$236M | -$196M |
| Net IncomeAfter-tax profit | -$212M | -$204M |
| Free Cash FlowCash after capex | -$181M | -$76M |
| Gross MarginGross profit ÷ Revenue | — | +89.4% |
| Operating MarginEBIT ÷ Revenue | — | -90.9% |
| Net MarginNet income ÷ Revenue | — | -93.8% |
| FCF MarginFCF ÷ Revenue | — | -35.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +83.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -67.3% | -2.5% |
RYTM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — IRON and RYTM each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | IRONDisc Medicine, In… | RYTMRhythm Pharmaceut… |
|---|---|---|
| Market CapShares × price | $2.6B | $6.6B |
| Enterprise ValueMkt cap + debt − cash | $2.5B | $6.8B |
| Trailing P/EPrice ÷ TTM EPS | -11.24x | -30.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 34.75x |
| Price / BookPrice ÷ Book value/share | 3.22x | 44.97x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — IRON and RYTM each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IRON leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
IRON delivers a -32.8% return on equity — every $100 of shareholder capital generates $-33 in annual profit, vs $-2 for RYTM. IRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RYTM's 1.77x. On the Piotroski fundamental quality scale (0–9), RYTM scores 5/9 vs IRON's 3/9, reflecting solid financial health.
| Metric | IRONDisc Medicine, In… | RYTMRhythm Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -32.8% | -2.0% |
| ROA (TTM)Return on assets | -30.2% | -45.2% |
| ROICReturn on invested capital | -38.0% | -70.1% |
| ROCEReturn on capital employed | -38.0% | -58.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 1.77x |
| Net DebtTotal debt minus cash | -$89M | $192M |
| Cash & Equiv.Liquid assets | $91M | $54M |
| Total DebtShort + long-term debt | $2M | $246M |
| Interest CoverageEBIT ÷ Interest expense | -45.75x | -12.41x |
IRON leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RYTM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RYTM five years ago would be worth $43,504 today (with dividends reinvested), compared to $5,637 for IRON. Over the past 12 months, IRON leads with a +55.1% total return vs RYTM's +48.9%. The 3-year compound annual growth rate (CAGR) favors RYTM at 79.4% vs IRON's 29.6% — a key indicator of consistent wealth creation.
| Metric | IRONDisc Medicine, In… | RYTMRhythm Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -14.6% | -8.4% |
| 1-Year ReturnPast 12 months | +55.1% | +48.9% |
| 3-Year ReturnCumulative with dividends | +117.5% | +477.3% |
| 5-Year ReturnCumulative with dividends | -43.6% | +335.0% |
| 10-Year ReturnCumulative with dividends | -34.4% | +220.8% |
| CAGR (3Y)Annualised 3-year return | +29.6% | +79.4% |
RYTM leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IRON and RYTM each lead in 1 of 2 comparable metrics.
Risk & Volatility
IRON is the less volatile stock with a 1.01 beta — it tends to amplify market swings less than RYTM's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RYTM currently trades 78.7% from its 52-week high vs IRON's 67.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IRONDisc Medicine, In… | RYTMRhythm Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.01x | 1.04x |
| 52-Week HighHighest price in past year | $99.50 | $122.20 |
| 52-Week LowLowest price in past year | $40.00 | $55.31 |
| % of 52W HighCurrent price vs 52-week peak | +67.9% | +78.7% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 67.9 |
| Avg Volume (50D)Average daily shares traded | 417K | 853K |
Evenly matched — IRON and RYTM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IRON as "Buy" and RYTM as "Buy". Consensus price targets imply 54.2% upside for IRON (target: $104) vs 45.5% for RYTM (target: $140).
| Metric | IRONDisc Medicine, In… | RYTMRhythm Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $104.14 | $140.00 |
| # AnalystsCovering analysts | 11 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RYTM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). IRON leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallRhythm Pharmaceuticals, Inc. (RYTM)Leads 2 of 6 categories
Loading custom metrics...
IRON vs RYTM: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IRON or RYTM a better buy right now?
Analysts rate Disc Medicine, Inc.
(IRON) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IRON or RYTM?
Over the past 5 years, Rhythm Pharmaceuticals, Inc.
(RYTM) delivered a total return of +335. 0%, compared to -43. 6% for Disc Medicine, Inc. (IRON). Over 10 years, the gap is even starker: RYTM returned +220. 8% versus IRON's -34. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IRON or RYTM?
By beta (market sensitivity over 5 years), Disc Medicine, Inc.
(IRON) is the lower-risk stock at 1. 01β versus Rhythm Pharmaceuticals, Inc. 's 1. 04β — meaning RYTM is approximately 3% more volatile than IRON relative to the S&P 500. On balance sheet safety, Disc Medicine, Inc. (IRON) carries a lower debt/equity ratio of 0% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — IRON or RYTM?
On earnings-per-share growth, the picture is similar: Rhythm Pharmaceuticals, Inc.
grew EPS 28. 3% year-over-year, compared to -51. 8% for Disc Medicine, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IRON or RYTM?
Disc Medicine, Inc.
(IRON) is the more profitable company, earning 0. 0% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRON leads at 0. 0% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — RYTM leads at 89. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IRON or RYTM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IRON or RYTM better for a retirement portfolio?
For long-horizon retirement investors, Rhythm Pharmaceuticals, Inc.
(RYTM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +220. 8% 10Y return). Both have compounded well over 10 years (RYTM: +220. 8%, IRON: -34. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IRON and RYTM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IRON is a small-cap quality compounder stock; RYTM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.